Since joining the University of Calgary in 1991, Dr. Kubes research has continued to investigate the mechanisms leading to white cell recruitment in cardiovascular disorders. Dr. Kubes and his team identified that an endogenously produced gas, nitric oxide, functions to reduce leukocyte recruitment. This work has subsequently branched out into areas of infection and autoimmunity. They also examined a role for ATIII (antithrombin III) as a potential intervention in ischemia/reperfusion as well as sepsis; it was discovered that although ATIII was very effective in preventing leukocyte recruitment in ischemia/reperfusion it had little impact on recruitment in endotoxemia. In addition to ATIII they are also examining the importance of IVIG (intravenous immunoglobulin) in inflammation models. In translational work in collaboration with ICU physicians Dr. Kubes’ team has identified a novel adhesion molecule on neutrophils in septic patients.
Paul Kubes began his research as a graduate student at Queen's University in 1984 in the area of Cardiovascular Physiology. In 1988 he moved to Louisiana State University (LSU) Medical Center to start a post-doctoral fellowship trying to understand why there is excessive inflammation associated with heart attacks and strokes. As part of a group at LSU, he developed a system to visualize the behaviour of white cells in blood vessels under normal conditions and during low flow states (e.g., during an ischemic episode in the heart). They found that under these pathological conditions there is a very profound recruitment of white cells into the afflicted tissue.
Dr. Kubes took a position as Assistant Professor in 1991 at the University of Calgary and is presently a full professor at the University of Calgary’s Faculty of Medicine. In addition to this, he is also an AHFMR scientist, a Canada Research Chair, and the founding Director of the new Institute of Infection, Immunity and Inflammation. Together with a group of nine other professors at the University of Calgary, and with the help of a substantial grant from the Canadian Institutes of Health Research (CIHR), he has also created a training program geared towards elucidating the cellular, molecular, and physiologic mechanisms of white cell recruitment in immune disease.
Dr. Kubes sits on national and international grant panels, and is currently a board member of the Journal of Experimental Medicine.
In recognition of his research contributions Dr. Kubes has received:
Since the beginning of his independent research career Dr. Kubes has been continuously supported in his research endeavours by the CIHR, Alberta Heritage Foundation for Medical Research, and from numerous societies including the Crohn’s & Colitis Foundation of Canada, Heart & Stroke Foundation of Canada, Multiple Sclerosis Society of Canada, and Bayer Canadian Blood Services/CIHR Partnership Fund. Presently, he holds eight peer-reviewed grants, four of which are CIHR grants. He is the principal grant holder of a CIHR Group Grant and a CIHR Training Program. Dr. Kubes is also the recipient of two Canadian Foundation of Innovation Grants. The first of which was funded by the Institute of Inflammation and the second was funded by the Alberta Virology Institute.
Dr. Kubes has published over 180 peer-reviewed papers and is regularly invited to national and international meetings and Universities to present his research findings.